Optos to Participate in International Vision Expo East
3/21/2007
MARLBOROUGH, MA, March 21, 2007 – Optos, a leading medical technology company for the design, development, manufacturing, and marketing of retinal imaging devices, will host key educational activities at the International Vision Expo East taking place on March 22-25, 2007, New York, NY.
Optos will hold its Optos Academy XT meeting on Wednesday, March 21st at 1:00 pm. A popular workshop series, the Optos Academy XT is for Optos Partners and other interested doctors which will highlight techniques and best practices created to enable clinicians to achieve the highest level of success with Optos’ technology. The Academy will feature two highly-regarded speakers – Jeffry Gerson OD, FAAO, and Kim Castleberry, OD. Dr. Gerson will provide two educational presentations titled, “Retina Grand Rounds” and “Contemporary Care of the Diabetic Patient.” Dr. Castleberry will give his popular lecture titled, “Diagnosis, Coding, and Reimbursement Associated with Vitreoretinal Conditions.”
In addition to the Optos Academy XT, Optos will also hold an exclusive educational event titled, “Improve Your View of the Retina with the optomap® Retinal Exam, Digital Panoramic Scanning Laser Ophthalmoscope Showcase,” by esteemed speaker, Noah Eger, OD, FAAO on Saturday, March 24th at 6:30 pm.
“Implementing the optomap® Retinal Exam into our practice has accelerated our practice into the 21st century. It has allowed our doctors to provide a higher quality exam, and our patients really appreciate our investment in their ocular and visual well being,” stated Dr. Eger. “We are proud to be affiliated with a company that continues to make a substantial commitment to improving the technology and look forward to growing with the next generation of Optos’ V2 software.”
Optos also encourages Vision Expo East attendees to attend the following educational sessions: “Retinal Symposium - Part I: Disorders Within the Vascular Arcades” by Jerome Sherman, OD and Richard Madonna, OD; “Retinal Symposium - Part II: Disorders Beyond the Vascular Arcades” by Jerome Sherman, OD & Richard Madonna, OD; “The Office of the Future: Technology That Will Change the Way We Practice” by Scot Morris, OD; “Diagnosing and Managing Diabetic Retinopathy: Essentials for the Primary Care OD” by Anthony Cavallerano, OD; and “Technological Tidbits for the 21st Century” by Noah Eger, OD and Michael Cymbor, OD.
Representatives from Optos will be at its booth, #1124, throughout Vision Expo East to meet with Optos Partners as well as educate interested attendees on Optos’ technology. Optos encourages attendees to stop by its booth to receive a complimentary optomap® Retinal Exam and learn how this innovative technology – used by more than 2,500 eye care practitioners worldwide – helps with the detection and diagnosis of both eye and non-eye related conditions.
Note to Editors
Optos plc is a leading and rapidly growing medical technology company for the design, development, manufacturing and marketing of devices that image the retina, the light-sensitive area at the back of the eye. Optos' platform technology is the Panoramic200
Scanning Laser Ophthalmoscope device - known as the P200. In a quarter of a second the P200 device produces a high resolution image of up to 200 degrees or approximately 82 percent of the retina in a single capture. The image - branded the optomap® Retinal Exam - provides eye care practitioners with clinically useful information that facilitates the early detection of disorders and diseases evidenced in the retina, such as glaucoma, diabetic retinopathy and age-related macular degeneration.
The Company has gained regulatory clearance (CE and FDA 510(k)) to market a second device - P200MA. The P200MA is aimed at the specialist ophthalmic and medical as opposed to the primary care market. It is designed to produce an angiographic retinal image called optomap® fa that supports medical procedures by providing enhanced diagnostic, monitoring and treatment capabilities. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as diabetes, hypertension and certain cancers. Optos’ technology provides an unequalled combination of wide-field retinal imaging, speed and convenience for both practitioner and patient and can help save sight and save lives.
Optos estimates that its P200 device is targeting a recurring US$2 billion market opportunity. As at 30 September 2006 Optos had 232 employees serving more than 2,500 customers in the Company’s existing markets, currently the USA, Canada, UK and Germany. Optos plc is headquartered in Dunfermline, Scotland and was admitted to the Main Market of the London Stock Exchange on 15 February 2006 trading under the symbol OPTS.
Optos is incorporated in Scotland under the Companies Act 1985 with registered number SC139953. The Company maintains its Registered Office at Queensferry House, Carnegie Business Campus, Dunfermline, Scotland KY11 8GR United Kingdom.